Carnosic acid inhibits NLRP3 inflammasome activation by targeting both priming and assembly steps

Int Immunopharmacol. 2023 Mar:116:109819. doi: 10.1016/j.intimp.2023.109819. Epub 2023 Feb 2.

Abstract

Carnosic acid (CA) is a polyphenolic diterpene from rosemary extract with anti-tumor and anti-inflammatory activities. Numerous reports have focused on its anti-tumor ability, while the exact mechanisms underlying its anti-inflammation remains unclear. Here, we have identified that CA is a potent inhibitor of NLRP3 inflammasome in vitro and in vivo. CA not only reduces NLRP3 expression by blocking NF-κB activation, but also inhibits NLRP3 inflammasome assembly and activation by suppressing mitochondrial ROS production and interrupting NLRP3-NEK7 interaction. Furthermore, in mouse models, CA alleviates lipopolysaccharide-induced acute systemic inflammation and MSU-induced peritonitis via NLRP3. Taken together, our data demonstrated the inhibitory effect of CA on NLRP3 inflammasome and pointed out the potential application of CA in the treatment of NLRP3-driven diseases.

Keywords: ASC speck; Acute kidney injury; Acute lung injury; Carnosic acid; NLRP3 inflammasome; Sepsis.

MeSH terms

  • Abietanes / pharmacology
  • Abietanes / therapeutic use
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Inflammasomes* / metabolism
  • Mice
  • Mice, Inbred C57BL
  • NLR Family, Pyrin Domain-Containing 3 Protein* / metabolism

Substances

  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • salvin
  • Abietanes
  • Anti-Inflammatory Agents
  • Nlrp3 protein, mouse